Vanguard Capital Management
BCRX icon

Vanguard Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vanguard Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114M Buy
11,364,236
+228,474
+2% +$2.07M ﹤0.01% 1498
2026
Q1 		$106M Buy
+11,135,762
New +$86.5M ﹤0.01% 1441

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management's BCRX Position: Q2 2026 in Review

Vanguard Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 2.1% in Q2 2026, buying an estimated $2.07M and bringing the position to 11,364,236 shares worth $114M. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

Vanguard Capital Management first reported a position in BCRX in Q1 2026 and has held it in 2 quarters since. 315 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Vanguard Capital Management held 11,364,236 shares of BioCryst Pharmaceuticals worth $114M as of Q2 2026.
  • Vanguard Capital Management bought 228,474 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.07M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1498 holding.
  • Vanguard Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 315 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.